The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adma Biologics is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ADMA's full-year earnings has moved 5.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ADMA has moved about 382.7% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.5%. This shows that Adma Biologics is outperforming its peers so far this year.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 45.1%.
For Addex Therapeutics Ltd. Sponsored ADR, the consensus EPS estimate for the current year has increased 236.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, which includes 504 individual stocks and currently sits at #60 in the Zacks Industry Rank. Stocks in this group have lost about 6.3% so far this year, so ADMA is performing better this group in terms of year-to-date returns.
Addex Therapeutics Ltd. Sponsored ADR, however, belongs to the Medical - Drugs industry. Currently, this 170-stock industry is ranked #65. The industry has moved -3.9% so far this year.
Investors with an interest in Medical stocks should continue to track Adma Biologics and Addex Therapeutics Ltd. Sponsored ADR. These stocks will be looking to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Addex Therapeutics Ltd. Sponsored ADR (ADXN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。